Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
390 results about "Endothelial Growth Factors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Vascular endothelial growth factor (VEGF): A substance made by cells that stimulates new blood vessel formation, a mitogen for vascular endothelial (vessel lining) cells.
Antibody fragment-polymer conjugates and uses of same
Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and / or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also described are conjugates directed against human vascular endothelial growth factor (VEGF), human p185 receptor-like tyrosine kinase (HER2), human CD20, human CD18, human CD11a, human IgE, human apoptosis receptor-2 (Apo-2), human tumor necrosis factor-α (TNF-α), human tissue factor (TF), human α4β7 integrin, human GPIIb-IIIa integrin, human epidermal growth factor receptor (EGFR), human CD3, and human interleukin-2 receptor α-chain (TAC) for diagnostic and therapeutic applications.
Owner:GENENTECH INC
Bispecific antibody to VEGF/PDGFR beta and application thereof
InactiveCN102250246AInhibition of newbornsGood tumor activityHybrid immunoglobulinsAntibody ingredientsSingle-Chain AntibodiesBispecific monoclonal antibody
The invention relates to a medicine of a bispecific monoclonal antibody, and especially to a medicine of a bispecific monoclonal antibody to human vascular endothelial growth factor (VEGF / VEGF-A) and platelet-derived growth factor receptor (PDGFR) for resistance to angiogenesis of tumor. The bispecific antibody to VEGF / PDGFR beta provided in the invention is characterized in that: a monoclonal antibody to VEGF is used as the base for the antibody and a single chain antibody to PDGFR beta is connected with the terminal of FC segment of the monoclonal antibody to VEGF to form the bispecific antibody to VEGF / PDGFR beta. The bispecific antibody related to in the invention is obtained by employing technical means like gene engineering and constructing antibody segments which identify VEGF and PDGFR beta in a same antibody molecule that can be specifically bound with the two antibody segments; the effect of the bispecific antibody on inhibiting angiogenesis of tumor issue is obviously superior to that of a single antibody to VEGF; and the bispecific antibody has good activity in resisting tumors.
Owner:CHANGZHOU ADAM BIOTECH
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
InactiveUS20050171039A1Improves various propertyImprove the immunityBiocideSugar derivativesDiseaseFactor ii
The present invention concerns methods and reagents useful in modulating vascular endothelial growth factor (VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D) and / or vascular endothelial growth factor receptor (e.g., VEGFR1, VEGFR2 and / or VEGFr3) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against VEGF and / or VEGFr gene expression and / or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of VEGF and / or VEGFr expression or activity.
Owner:SIRNA THERAPEUTICS INC
Encased stent
InactiveUS7311727B2Prevent restenosisImprove scalabilityStentsSurgeryCell Cycle InhibitionPolyethylene glycol
An encased stent that discourages restenosis by having a homogenous endothelial cell lining along the inner wall of the stent. The endothelial cell lining may be coated on the stent before the stent is placed in the artery, or the endothelial cell lining may be grown after placement by several factors that encourage such growth and discourage restenosis. The endothelial cells to coat the stent may be genetically modified to enhance the growth of the endothelial cells into a homogeneous lining. The stent has a continuous lining in the form of a multi-layer polymer coating, including a conducting biocorrosion inhibiting layer and a continuous film of polyurethane coupled by a coupling agent to polyethylene glycol. Various drugs and cell factors may be incorporated into the lining, such as anti-thrombin, anti-inflammatory and anti-coagulant drugs, cell cycle inhibitors, and vascular endothelial growth factors.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS
Inhibitors of type 2 vascular endothelial growth factor receptors
ActiveUS20070148126A1Improve pharmacokineticsIncrease target binding affinityOrganic active ingredientsSenses disorderVascular Endothelial Growth Factor ReceptorDrug biological activity
The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
Owner:BRISTOL MYERS SQUIBB CO
Pharmacokinetic modulation and compositions for modified Fn3 polypeptides
ActiveUS20070160533A1Improve continuityReduce the differenceSenses disorderPeptide/protein ingredientsVascular Endothelial Growth Factor ReceptorDrug biological activity
Owner:BRISTOL MYERS SQUIBB CO
Bispecific Anti-VEGF/Anti-ANG-2 Antibodies and their use in the Treatment of Ocular Vascular Diseases
ActiveUS20140017244A1Highly valuable propertyDiffusion slowAnimal cellsSenses disorderVascular diseaseBispecific antibody
The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF / VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Owner:ROCHE GLYCART AG
Vascular endothelial growth factor fusion constructs and uses thereof
InactiveUS20050037967A1Inhibiting metastatic spreadInhibiting vascularizationPeptide/protein ingredientsAntibody mimetics/scaffoldsGeloninAbnormal tissue growth
The 121-amino acid isoform of vascular endothelial growth factor (VEGF121) is linked by a flexible G4S tether to a cytotoxic molecule such as toxin gelonin or granzyme B and expressed as a soluble fusion protein. The VEGF12, fusion protein exhibits significant anti-tumor vascular-ablative effects that inhibit the growth of primary tumors and inhibit metastatic spread and vascularization of metastases. The VEGF121 fusion protein also target osteoclast precursor cells in vivo and inhibits osteoclastogenesis.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
InactiveUS20050148530A1Improves various propertyImprove the immunityBiocideSugar derivativesDiseaseFactor ii
The present invention concerns methods and reagents useful in modulating vascular endothelial growth factor (VEGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D) and / or vascular endothelial growth factor receptor (e.g., VEGFR1, VEGFR2 and / or VEGFr3) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (mRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against VEGF and / or VEGFr gene expression and / or activity. The small nucleic acid molecules are useful in the diagnosis and treatment of cancer, proliferative diseases, and any other disease or condition that responds to modulation of VEGF and / or VEGFr expression or activity.
Owner:SIRNA THERAPEUTICS INC
Method for preparing biodegradable polymer self-expansion type intravascular stent based on 3D printing technology
InactiveCN105771003AImprove long-term patencyAvoid axial shorteningSurgeryPharmaceutical delivery mechanismBiocompatibility TestingBiodegradable polymer
The invention relates to a method for preparing a biodegradable polymer self-expansion type intravascular stent based on 3D printing technology.The method includes the specific steps of synthesizing polylactic acid-based shape-memory polyurethane / Fe304 nanocomposite material with good biocompatibility and biodegradability, and making the composite material into the intravascular stent through the Fused Deposition Modeling technology.In addition, in order to increase the blood vessel endothelium repair speed, sirolimus, heparin, endothelial growth factors or the like are selectively introduced to the stent surface through electrostatic spinning.A 'time'dimension is added for the shape-memory function of the base material, and combined with the 3D printing technology, a 4D forming concept is given to the stent.By means of the magnetocaloric effect of Fe304, shape recovery of the shape-memory polymer can be remotely excited, so that the intravascular stent expands automatically, balloon dilatation is not required during stent implantation, axial shortening during balloon dilatation and radial resilience during withdraw of the stent are avoided, and damage of blood vessels is reduced to a minimum level.In addition, the introduction of Fe304 solves the problem that a polymer stent has poor development.
Owner:TONGJI UNIV
Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
ActiveUS9695233B2Low viscosityHighly valuable propertySenses disorderImmunoglobulins against growth factorsVascular diseaseBispecific antibody
The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF / VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Owner:ROCHE GLYCART AG
Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies
ActiveUS8945552B2Guaranteed efficient growthInhibition is effectiveAnimal cellsHybrid immunoglobulinsAntibodyEndothelial Growth Factors
Owner:F HOFFMANN LA ROCHE INC
Human resource vessel endothelium growth factor monoclonal antibody and preparation method thereof
InactiveCN101148474AImmunoglobulins against animals/humansAntibody ingredientsImmunogenicityAntitumor activity
The present invention discloses one new kind of humanized human vessel endothelium growth factor monoclonal antibody, the hybridoma cell for preparing the monoclonal antibody and the preparation process of the monoclonal antibody. The monoclonal antibody of the present invention can combine with VEGF antigen in high specificity, very high affinity and very low immunogenicity, and has obvious antitumor activity.
Owner:SHANGHAI GENON BIOENG
Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors
This invention relates to compounds of formula (I) and (II) that are useful in treating vascular endothelial growth factor (VEGF)-mediated disorders, particularly endometriosis and acute macular degenerative disorder. The invention also relates to a topical system for the treatment of acute macular degenerative disorder comprising a VEGF inhibitor.
Owner:DSPI
Degradable wound repair material and preparation method thereof
InactiveCN103830768AGood biocompatibilityGood for degradation and absorptionAbsorbent padsBandagesWhite blood cellPancreatic hormone
The invention relates to a degradable wound repair material and a preparation method thereof. The degradable wound repair material includes a matrix component and an auxiliary component, wherein the matrix component includes a protein ingredient, and the auxiliary component includes at least one of an antibacterial agent and an active factor. Specifically, the antibacterial agent is a synthetic antibacterial drug, an inorganic antibacterial agent, an organic antibacterial agent, or a natural antibacterial agent, and the active factor is at least one of the following active factors: an epidermal growth factor, an FGF vascular endothelial growth factor, a platelet-derived growth factor, a platelet activating factor, an insulin-like growth factor, a tumor necrosis factor, interleukin, colony stimulating factor-1, various bone morphogenetic proteins or transforming growth factors. By loading the antibacterial agent and active factor component on the basis of the matrix component, the degradable wound repair material provided by the invention can have biological activity on the basis of meeting degradability, can better promote wound repair, and has good anti-infection properties during use.
Owner:SHENZHEN LANDO BIOMATERIALS
Regulation of vascular endothelial growth factor (VEGF) gene expression in tissue via the application of electric and/or electromagnetic fields
InactiveUS20090018613A1Promote angiogenesisInhibit tumor growthInternal electrodesExternal electrodesLigament healingHuman DNA sequencing
Methods and devices for the regulation of gene expression in tissue by applying an electric and / or electromagnetic field generated by specific and selective signals so as to treat diseases, conditions, and / or tissue. Gene expression is the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are described for the regulation of Vascular Endothelial Growth Factor (VEGF) protein gene expression in endothelial cells of various targeted tissues via the capacitive coupling or inductive coupling (e.g., by electrodes or one or more coils or other field generating devices disposed with respect to the targeted cells) of specific and selective signals to the cells of these tissues, where the resultant electric and / or electromagnetic fields treat diseased or injured tissues. The resulting methods and devices are useful for the targeted treatment of peripheral vascular disease, cardiovascular disease, macular degeneration, wound healing, tendon and ligament healing, in preventing tumor growth or spread, and other conditions in which VEGF protein may be implicated.
Owner:GENESTIM
Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
InactiveUS6965010B2Improve purification effectExtended half-lifeOrganic active ingredientsFungiNucleotideVascular endothelium
The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors.
Owner:VEGENICS PTY LTD
Method for preparing essence of stem cell factor with anti-aging effect
InactiveCN108186548APromote growth and proliferationRelieve agingCosmetic preparationsToilet preparationsGlycerolRepair skin
The invention discloses a method for preparing essence of stem cell factor with an anti-aging effect. The method comprises the steps that step 1, human umbilical cord mesenchyma stem cells are prepared and cultured, stem cell culture supernatant is collected, concentrate is obtained after concentration is conducted, and the concentrate is further frozen and dried to prepare the lyophilized powderof the stem cell factor; step 2, the components of, by volume, 0.1-1% of hyaluronic acid, 1-10% of glycerol, 0.1-1% of collagen protein, 0.1-1% of tea polyphenols and the balance water are mixed to obtain solvent; step 3, the solvent is added into the lyophilized powder of the stem cell factor to be thoroughly dissolved to obtain the essence of the stem cell factor. The prepared essence of the stem cell factor comprises multiple kinds of cell active factor components such as epidermal growth factor, vascular endothelial growth factor, hepatocyte growth factor, nerve growth factor and the like,the essence can nourish skin, promote skin repairing and regenerating, resist wrinkles, remove colored patches and the like, and the essence has better application value in the field of medical beauty.
Owner:上海莱馥生命科学技术有限公司
Modified binding proteins inhibiting the VEGF-A receptor interaction
ActiveUS8710187B2Senses disorderPeptide/protein ingredientsAnkyrin Repeat ProteinPolyethylene glycol
The present invention relates to binding proteins specific for Vascular Endothelial Growth Factor A (VEGF-A), in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx (wherein xxx denotes the amino acid length of the VEGF-A mature protein) binding to Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2). Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.
Owner:MOLECULAR PARTNERS AG
Device for maintaining vascularization near an implant
InactiveUS7332330B2Minimization requirementsOutput maximizationBioreactor/fermenter combinationsBiological substance pretreatmentsFiberGenetically engineered
A device and a method of maintaining vascularization near an implant, especially a bioartificial hemofilter. By associating cells that excrete angiogenic factors with such an implant, vascularization to the tissue surrounding the implant can be maintained. In a bioartificial hemofilter, this facilitates filtrate transport to a collection fiber for drainage from the body. The cells can be genetically engineered, for example using an adenovirus vector encoding for vascular endothelial growth factor. Myoblasts and myotubes may be used in one embodiment of the present invention.
Owner:CYTOPHERX INC +1
Novel VEGF mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
InactiveUS20130101628A1Improve biological activityCheap productionPeptide/protein ingredientsAntibody mimetics/scaffoldsPhosphorylationTherapeutic angiogenesis
Disclosed herein is a completely synthetic cell-free therapy based on peptide amphiphile nanostructures designed to mimic the activity of vascular endothelial growth factor (VEGF), one of the most potent angiogenic signaling proteins. The VEGF-mimetic filaments disclosed herein were found to induce phosphorylation of VEGF receptors and induce pro-angiogenic behavior in endothelial cells, indicated by an enhancement in proliferation, survival and migration in vitro.
Owner:NORTHWESTERN UNIV
Hpma-polyamine conjugates and uses therefore
InactiveUS20060014695A1Prevent proliferationStimulate immune responsePeptide/protein ingredientsGenetic material ingredientsSomatostatin analogTreatment effect
The inventions provide compositions and methods for nucleic acid delivery comprising IIPMA conjugated to a polyamine. These compositions have the benefit of the steric hindrance of HPMA and the nucleic acid binding capability of a polyamine. Useful polyamines for this purpose include spermine, spermidine and their analogues, and DFMO. These polyamines have the ability not only to bind nucleic acids, but also have anti-cancer effects themselves. The compounds provided can also include ligand binding domains, such as vascular endothelial growth factors, somatostatin and somatostatin analogs, transferring, melanotropin, ApoE and ApoE peptides, von Willebrand's factor and von Willebrand's factor peptides, adenoviral fiber protein and adenoviral fiber protein peptides, PD 1 and PD 1 peptides, EGF and EGF peptides, RGD peptides, CCK peptides, antibody and antibody fragments, folate, pyridoxyl and sialyl-LewisX and chemical analogs. Methods for using these compositions to achieve a therapeutic effect, including for vaccination, are also provided.
Owner:UNIV OF MARYLAND
Therapeutic molecules for modulating stability of vegf
InactiveUS20090048191A1Facilitate reduced gene expressionHigh expressionOrganic active ingredientsSenses disorderMammalAngiogenesis growth factor
This present invention discloses nucleic acid compositions and methods that are useful for treating ischemic conditions in animals, particularly in mammals such as humans. Specifically, the invention discloses nucleic acid molecules comprising or encoding a sequence that modulates the stability of a transcript from a vascular endothelial growth factor gene, as well as pharmaceutical compositions containing such molecules, which arm useful for modulating angiogenesis or vascularization, especially in methods for treating ischemic conditions.
Owner:LIONS EYE INST OF WESTERN AUSTRALIA
Composition for hair, and hair growth liquid
ActiveCN108201513AResilientNot easy to lose hairCosmetic preparationsHair cosmeticsExternal applicationTelogen hair
The invention discloses a hair growth composition, wherein fullerene is dissolved in an acceptable external application carrier such as grease, and then the fullerene and other components are compounded through solubilizing or emulsifying to form the composition beneficial for hair and scalp. According to the present invention, the composition can achieve the long hair growth period of mice, shorten the hair rest period of mice, make hair lush, dense and black, significantly increase the number of hair follicles, and effectively promote the secretion of the endothelial growth factors of hair;and the composition is suitable for various problems of alopecia, hair loss, damage on hair and the like, can solve the problems of people with alopecia and hair loss, can provide effects of hair fixation, hair growth, hair development and the like within a short time, and has wide application prospect.
Owner:BEIJING FUNAKANG BIOTECH CO LTD +1
Preparation method of tissue-regeneration-promoting controlled-release multiple-growth-factor self-assembled coating
InactiveCN103751847AIn situ induced activationRegulated releaseProsthesisBiocompatibilityOrganic polymer
Owner:TONGJI UNIV
Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
ActiveUS20060166277A1Diagnosing and effectively treatingSave maternalMicrobiological testing/measurementDisease diagnosisPregnancyUdp glycosyltransferase
Disclosed herein are methods for diagnosing or treating pregnancy related hypertensive disorders that include the use of a polypeptide or a nucleic acid encoding a polypeptide selected from the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, lanosterol synthase, calcium / calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehyrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease
Disclosed herein is a rational, multi-tier approach to the administration of growth factor proteins in the treatment of heart disease. Also disclosed is a method to evaluate the effectiveness of the administration of growth factor proteins comprising the clinical assay of CPK-MB levels in a patient undergoing treatment with growth factor proteins. In addition, there is disclosed a method for treatment of heart disease comprising administration of a therapeutically effective amount of a growth factor protein by oral inhalation therapy.
Owner:FRANCO WAYNE P
In vivo chemical stabilization of vulnerable plaque
InactiveUS20110218517A1Less-invasive procedureOrganic active ingredientsBalloon catheterVulnerable plaqueIn vivo
Procedures for the stabilization of vulnerable plaque can comprise identification of the vulnerable plaque and the delivery of a stabilization composition to the location of the vulnerable plaque. For example, the stabilization composition can be delivered to an isolated portion of the vessel with the vulnerable plaque and / or alternatively or additionally using a profusion balloon that delivers the stabilization composition at the vessel wall near the vulnerable plaque. Suitable stabilization compositions can comprise a collagen crosslinking agent, an elastin stabilization agent, VEGF or a combination thereof. Vascular endothelial growth factor (VEGF) can be used to encourage endothelialization of the vessel wall near the vulnerable plaque.
Owner:OGLE MATTHEW F +1
Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
ActiveUS20110237650A1Modulate its functionOrganic active ingredientsSenses disorderDiseaseVascular endothelial growth inhibitor
Oligonucleotide compounds modulate expression and / or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VEGF) comprise administering one or more Oligonucleotide compounds designed to inhibit the VEGF natural antisense transcript to patients.
Owner:CURNA INC
Human VEGF detection combination reagent, reagent box and use method thereof
ActiveCN104530234AImprove featuresHigh sensitivityImmunoglobulins against growth factorsBiological testingMurine Monoclonal Antibody 2B8True positive rate
The invention discloses a murine monoclonal antibody resistant to human vascular endothelial growth factors (VEGFs), a combination reagent containing the murine monoclonal antibody and used for detecting the human VEGF level in a biological sample, a reagent box containing the combination reagent and a use method of the reagent box. The combination KD value of the murine monoclonal antibody and the human VEGFs reaches 0.01 nM, and the combination reagent containing the murine monoclonal antibody and the reagent box containing the combination reagent have the advantages of being high in detection sensitivity and specificity.
Owner:AMPSOURCE BIOPHARMA (SHANGHAI) INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com